Home
About IBT
Vision and Mission
IBT History
Management
Board of Directors
Advisory Board
Families
Health Care Professionals
Pipeline
IBP-9414
IBP-1016
Investors & Media
Shares
Presentations
Share Issue
Ownership Structure
Corporate Governance
Calendar
Financial Reports
Press Releases
News
Investors & Media Contact
Subscribe
Contact Us
Career
En
Sv
Home
About IBT
Vision and Mission
IBT History
Management
Board of Directors
Advisory Board
Families
Health Care Professionals
Pipeline
IBP-9414
IBP-1016
Investors & Media
Shares
Presentations
Share Issue
Ownership Structure
Corporate Governance
Calendar
Financial Reports
Press Releases
News
Investors & Media Contact
Subscribe
Contact Us
Career
News
IBT has relocated to a new office
Come visit us at our new office at Bryggargatan 10, 111 21 Stockholm, Sweden.
October 1, 2015
Latest news
A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
Nomination Committee appointed for the 2022 Annual General Meeting (AGM) in Infant Bacterial Therapeutics (IBT).
Next recruitment milestone reached in IBT’s Phase III Study.
After safety review The Connection study is now again open to recruit the smallest infants.
This site uses cookies – small text-based files that are placed on your device to help us provide a better user experience.
Find out more.
Okay, thanks
